Alpha Tau Medical Stock Price, News & Analysis (NASDAQ:DRTS) $3.20 -0.01 (-0.31%) (As of 05:28 PM ET) Add Compare Share Share Today's Range$3.08▼$3.3350-Day Range$2.79▼$3.8952-Week Range$2.75▼$5.95Volume42,863 shsAverage Volume55,661 shsMarket Capitalization$221.98 millionP/E RatioN/ADividend YieldN/APrice Target$13.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Alpha Tau Medical MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside316.7% Upside$13.33 Price TargetShort InterestHealthy0.17% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.46) to ($0.54) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.21 out of 5 starsMedical Sector438th out of 949 stocksSurgical & Medical Instruments Industry57th out of 95 stocks 3.5 Analyst's Opinion Consensus RatingAlpha Tau Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.33, Alpha Tau Medical has a forecasted upside of 316.7% from its current price of $3.20.Amount of Analyst CoverageAlpha Tau Medical has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.17% of the float of Alpha Tau Medical has been sold short.Short Interest Ratio / Days to CoverAlpha Tau Medical has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alpha Tau Medical has recently decreased by 8.18%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlpha Tau Medical does not currently pay a dividend.Dividend GrowthAlpha Tau Medical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DRTS. Previous Next 2.8 News and Social Media Coverage News SentimentAlpha Tau Medical has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Alpha Tau Medical this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alpha Tau Medical insiders have not sold or bought any company stock.Percentage Held by Insiders39.50% of the stock of Alpha Tau Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.47% of the stock of Alpha Tau Medical is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Alpha Tau Medical are expected to decrease in the coming year, from ($0.46) to ($0.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alpha Tau Medical is -9.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alpha Tau Medical is -9.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlpha Tau Medical has a P/B Ratio of 2.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Alpha Tau Medical Stock (NASDAQ:DRTS)Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.Read More DRTS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DRTS Stock News HeadlinesNovember 28, 2023 | finance.yahoo.comAlpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic CancerNovember 26, 2023 | americanbankingnews.comAnalyzing Intelligent Bio Solutions (NASDAQ:INBS) & Alpha Tau Medical (NASDAQ:DRTS)November 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 24, 2023 | americanbankingnews.comHC Wainwright Research Analysts Lift Earnings Estimates for Alpha Tau Medical Ltd. (NASDAQ:DRTS)November 21, 2023 | americanbankingnews.comAlpha Tau Medical's (DRTS) "Buy" Rating Reaffirmed at HC WainwrightNovember 20, 2023 | finance.yahoo.comAlpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck CancerNovember 19, 2023 | americanbankingnews.comAlpha Tau Medical (NASDAQ:DRTS) Price Target Cut to $8.00November 17, 2023 | markets.businessinsider.comAnalyst Ratings for Alpha Tau MedicalNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 16, 2023 | msn.comAlpha Tau Medical GAAP EPS of $0.31October 30, 2023 | finance.yahoo.comAlpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing FacilitySeptember 16, 2023 | finance.yahoo.comHere's Why We're Not Too Worried About Alpha Tau Medical's (NASDAQ:DRTS) Cash Burn SituationSeptember 14, 2023 | stockhouse.comAlpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel's Hadassah Medical CenterAugust 24, 2023 | finance.yahoo.comAlpha Tau Medical to Participate in September Investor ConferencesAugust 17, 2023 | finance.yahoo.comAlpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRTAugust 2, 2023 | finance.yahoo.comAlpha Tau Medical to Present at the Emerging Growth Conference on August 9th, 2023May 25, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Alpha Tau Medical Ltd (DRTS)May 24, 2023 | finance.yahoo.comAlpha Tau Medical to Participate in June Investor ConferencesMay 23, 2023 | msn.comRecap: Alpha Tau Medical Q1 EarningsMay 22, 2023 | finance.yahoo.comShould You Buy Alpha Tau Medical (DRTS) Ahead of Earnings?May 18, 2023 | markets.businessinsider.comAlpha Tau Medical Ltd (DRTS) Receives a Buy from H.C. WainwrightMay 17, 2023 | finance.yahoo.comAlpha Tau Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge UniversityMay 11, 2023 | finance.yahoo.comAlpha Tau Announces the Publication of its US Multicenter Pilot Skin Cancer Trial Results in JAMA Network OpenMay 3, 2023 | finance.yahoo.comAlpha Tau Medical to Present at Guggenheim Radiopharmaceuticals DayApril 24, 2023 | msn.comAlpha Tau Medical a new buy at HC Wainwright on proprietary radiation therapyMarch 8, 2023 | finance.yahoo.comAlpha Tau Announces Alpha DaRT™ Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) TrialMarch 1, 2023 | finance.yahoo.comAlpha Tau Announces Health Canada Authorization for Alpha DaRT Clinical Trial for the Treatment of Liver MetastasesSee More Headlines Receive DRTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alpha Tau Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/16/2023Today11/29/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/14/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DRTS CUSIPN/A CIK1871321 Webhealthcarecapitalcorp.com Phone972-3577-4115FaxN/AEmployees94Year FoundedN/APrice Target and Rating Average Stock Price Target$13.33 High Stock Price Target$23.00 Low Stock Price Target$8.00 Potential Upside/Downside+315.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,760,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-26.02% Return on Assets-22.18% Debt Debt-to-Equity RatioN/A Current Ratio14.66 Quick Ratio18.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.30 per share Price / Book2.47Miscellaneous Outstanding Shares69,370,000Free Float41,971,000Market Cap$222.68 million OptionableNot Optionable Beta0.93 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Uzi Sofer (Age 53)CEO & Chairman Comp: $1.58MMr. Raphi Levy (Age 38)Chief Financial Officer Comp: $1.24MMr. Amnon Gat (Age 48)Chief Operations Officer Comp: $497kMr. Ronen Segal (Age 50)Chief Technology Officer Comp: $380kDr. Robert B. Den M.D. (Age 44)Chief Medical Officer & Member of Scientific Advisory Board Comp: $565kProf. Yona Keisari (Age 76)Chief Scientific Officer & Member of Scientific Advisory board Ms. Rebecca BeckerVice President of legalMr. Peter M. Melnyk (Age 61)Chief Commercial Officer Prof. Itzhak Kelson (Age 83)Chief Physics Officer & Member of Scientific Advisory Board Ms. Yael Zeiger (Age 40)Corporate Controller More ExecutivesKey CompetitorsProfound MedicalNASDAQ:PROFNeuroPaceNASDAQ:NPCEOrchestra BioMedNASDAQ:OBIOQuipt Home MedicalNASDAQ:QIPTAlpha Healthcare Acquisition Corp. IIINASDAQ:ALPAView All CompetitorsInstitutional OwnershipCitigroup Inc.Sold 322,793 shares on 11/9/2023Ownership: 0.022%Hoylecohen LLCBought 269,088 shares on 11/2/2023Ownership: 0.388%Levin Capital Strategies L.P.Bought 65,000 shares on 10/31/2023Ownership: 0.123%View All Institutional Transactions DRTS Stock Analysis - Frequently Asked Questions Should I buy or sell Alpha Tau Medical stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alpha Tau Medical in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DRTS shares. View DRTS analyst ratings or view top-rated stocks. What is Alpha Tau Medical's stock price target for 2024? 3 equities research analysts have issued 1 year price targets for Alpha Tau Medical's shares. Their DRTS share price targets range from $8.00 to $23.00. On average, they anticipate the company's stock price to reach $13.33 in the next year. This suggests a possible upside of 316.7% from the stock's current price. View analysts price targets for DRTS or view top-rated stocks among Wall Street analysts. How have DRTS shares performed in 2023? Alpha Tau Medical's stock was trading at $3.18 on January 1st, 2023. Since then, DRTS shares have increased by 0.6% and is now trading at $3.20. View the best growth stocks for 2023 here. Are investors shorting Alpha Tau Medical? Alpha Tau Medical saw a decrease in short interest in November. As of November 15th, there was short interest totaling 65,100 shares, a decrease of 8.2% from the October 31st total of 70,900 shares. Based on an average daily trading volume, of 26,500 shares, the short-interest ratio is presently 2.5 days. Currently, 0.2% of the shares of the company are short sold. View Alpha Tau Medical's Short Interest. When is Alpha Tau Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024. View our DRTS earnings forecast. How were Alpha Tau Medical's earnings last quarter? Alpha Tau Medical Ltd. (NASDAQ:DRTS) issued its quarterly earnings results on Thursday, November, 16th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.05. Who are Alpha Tau Medical's major shareholders? Alpha Tau Medical's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Hoylecohen LLC (0.39%), Levin Capital Strategies L.P. (0.12%) and Citigroup Inc. (0.02%). How do I buy shares of Alpha Tau Medical? Shares of DRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:DRTS) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alpha Tau Medical Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.